Visiomed Group Stock
€0.30
Your prediction
Visiomed Group Stock
Pros and Cons of Visiomed Group in the next few years
Pros
Cons
Performance of Visiomed Group vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Visiomed Group | 0.070% | -5.380% | 5.953% | -28.554% | -25.436% | -69.950% | - |
| Spineway | -30.000% | -9.091% | -71.193% | -99.255% | -99.340% | -99.991% | - |
| Implanet S.A. | 1.310% | -1.905% | -22.750% | -75.708% | -75.631% | -96.489% | -99.382% |
| Crossject S.A. | 3.700% | 9.586% | 10.501% | 39.879% | 40.944% | 29.149% | 275.812% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Considering the information at hand, it seems that Visiomed, a player in the Healthcare Equipment and Supplies industry, is navigating through some financial challenges, while also seizing on growth opportunities. These insights come from an examination of their financial statements and key ratios over the years.
Delving deeper into their financials, one might notice a pattern of increasing total assets from 2020 to 2022. This positive trajectory could signal an expanding business scope, perhaps due to strategic investments or acquisitions. Likewise, the gross profit, while still negative in 2020, improved over the next two years, hinting at stronger operational efficiency.
However, worries exist. Visiomed posted losses from 2020 to 2022, as indicated by negative net income figures. The current picture is one of ongoing financial strain, marked by a worsened net debt situation in 2022 and negative working capital in 2020. Plus, the negative free cash flow across the board raises liquidity concerns.